Medulloblastoma (Oncology) – Drugs in Development, 2021
- Pages: 556
- Published: December 2021
- Report Code: GMDHC13206IDB
Global Markets Direct’s, ‘Medulloblastoma – Drugs In Development, 2021’, provides an overview of the Medulloblastoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
– The report provides a snapshot of the global therapeutic landscape of Medulloblastoma
– The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved Medulloblastoma therapeutics and enlists all their major and minor projects
– The report assesses Medulloblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news related to pipeline therapeutics for Medulloblastoma
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Medulloblastoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
Acrivon Therapeutics Inc
Aettis Inc
Bayer AG
Biogenera SpA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
CDG Therapeutics Inc
Centessa Pharmaceuticals Plc
Chengdu Jinrui Foundation Biotechnology Co Ltd
Chimerix Inc
Cothera Bioscience Pty Ltd
Curis Inc
Curtana Pharmaceuticals Inc
Dalriada Therapeutics Inc
Dracen Pharmaceuticals Inc
Exelixis Inc
Gan & Lee Pharmaceuticals Co Ltd
Gennao Bio
Guangdong Zhongsheng Pharmaceutical Co Ltd
Immunomic Therapeutics Inc
IMPACT Therapeutics Inc
Kiadis Pharma NV
Kintara Therapeutics Inc
Kintor Pharmaceutical Ltd
Lumos Pharma Inc
MacroGenics Inc
Mana Therapeutics Inc
Midatech Pharma Plc
MimiVax LLC
Moleculin Biotech Inc
Mustang Bio Inc
Nanjing KAEDI Biotech Inc
Nascent Biotech Inc
Nektar Therapeutics
Novartis AG
Nurix Therapeutics Inc
Nuvectis Pharma Inc
Oncoheroes Biosciences Inc
Ono Pharmaceutical Co Ltd
Orphelia Pharma SAS
Oxurion NV
Pfizer Inc
Progenics Pharmaceuticals Inc
Sapience Therapeutics Inc
Senhwa Biosciences Inc
Shionogi & Co Ltd
Stemsynergy Therapeutics Inc
Sun Pharma Advanced Research Company Ltd
TheraBiologics Inc
VBI Vaccines Inc
Vyriad Inc
Wuhan Binhui Biotechnology Co Ltd
Y-mAbs Therapeutics Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.